The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“Tumour vessels become abnormal in almost all aspects of their structure and functio”
BackgroundSelf-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
“…angiogenic regulatory factors in their TME, or to pharmacological suppression of VEGF—evidence so-called ''vascular normalization ,'' in which vessels are less torturous, with better pericyte coverage, and improved and less erratic blood flow (De Bock et al., 2011; Goel et al., 2011; Jain, 2005).”
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
“The abnormal organization and structure of the tumor vasculature leads to tortuous and leaky vessels and heterogeneous blood flow”
BackgroundSelf-citation
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. https://app.cochat.ai/papers/10.1126/science.1104819
- The paper
- Jain, R. K. (2005). Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science. https://doi.org/10.1126/science.1104819
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.